Connections StemRIM

4599

JP3399690001

Pharmaceuticals

Market Closed - Japan Exchange 02:30:00 2026-10-02 EDT			5-day change	1st Jan Change
164.00 ^JPY	-3.53%		-6.29%	-37.64%

09-25	StemRIM Inc. Announces Patent Registration In South Korea For Use Of Redasemtide As Additional Therapeutic Indication Of Cartilage Disorders	CI
09-09	StemRIM Reports Earnings Results for the Full Year Ended July 31, 2026	CI

0

Listed companies

0

Private companies

11

Insiders

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Countries of related companies

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Companyâ€™s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

Employees

Sector

Pharmaceuticals

More about the company